Melbourne, Australia, June 18, 2026 — Australian biotechnology company Gelteq Ltd. (NASDAQ: GELS) has reported significant progress across its veterinary and human pharmaceutical programmes, with its first veterinary antiparasitic clinical trial now underway and additional financing secured to accelerate commercialization of its proprietary oral gel drug-delivery platform.
The company’s latest corporate update highlights continued progress toward a planned U.S. FDA regulatory submission for its veterinary antiparasitic programme later in 2026, positioning Gelteq to enter the global animal health market through an innovative oral drug-delivery technology designed to improve palatability, compliance and therapeutic performance.
Veterinary Programme Targets Expanding Animal Health Market
The veterinary clinical study follows Gelteq’s earlier announcement initiating its first animal-health clinical programme in May and forms a central component of the company’s dual-track commercialization strategy spanning both veterinary and human pharmaceuticals.
According to the company, the veterinary trial is expected to generate data supporting safety, efficacy and formulation performance required for regulatory submission while demonstrating the broader applicability of its proprietary gel-based delivery platform across animal health applications.
The company estimates the global animal health market will exceed US$78 billion in 2026, with antiparasitic therapies representing one of the largest and fastest-growing therapeutic categories due to increasing pet ownership, livestock production and parasite control requirements worldwide.
Financing Strengthens Commercial Roadmap
To support clinical development, Gelteq has secured up to US$3.5 million in strategic debt financing from an institutional investor.
The financing package comprises:
| Financing Component | Value |
|---|---|
| Initial funding received | US$1.0 million |
| Additional tranche (subject to shareholder approval) | US$2.5 million |
| Total facility | US$3.5 million |
The financing structure provides the company with additional working capital while allowing repayments to be deferred during the early commercialization phase. Shareholders are scheduled to vote on the remaining financing tranche on 18 June 2026.
Broader Pipeline Continues to Expand
Beyond veterinary medicine, Gelteq expects to commence its first human clinical trial during the next quarter while advancing preclinical diabetes research and expanding pharmaceutical applications for its oral gel delivery technology.
Recent milestones also include:
-
Successful canine palatability studies conducted with Kemin Industries, demonstrating strong acceptance of bitter active ingredients.
-
Establishment of a Center of Excellence in Guangdong, China, to accelerate product development and commercial manufacturing.
-
Manufacture of commercial products for a new East Asian customer, supporting international commercialization efforts.
